CoChat

Olaparib

Bochum, Sylvia, Berger, Stephanie, Martens, Uwe M. · 2018 · Recent Results in Cancer Research

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. It is rationally designed to act as a competitive inhibitor of NAD + at the catalytic site of PARP1 and PARP2, both members of the PARP family of enzymes that are central to the repair of DNA single-strand breaks (SSBs) mediated via the base excision repair (BER) pathway. Inhibition of the BER pathway by olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of deleterious double-strand breaks (DSBs). In cells with an intact homologous recombination (HR) pathway, these DSBs can be repaired effectively. However, in tumors with homologous recombination repair deficiencies, olaparib causes synthetic lethality through the combination of two molecular events that are otherwise nonlethal when occurring in isolation. Olaparib is already approved for the treatment of patients with recurrent ovarian cancer and a BRCA mutation, and it has been shown to provide clinically meaningful benefits among such patients. It has also shown promising activity in patients with metastatic breast or prostate cancer and a germline BRCA mutation. Besides its usage as a single agent, olaparib can also act either as a chemo- and/or radiosensitizer, due to its ability to potentiate the cytotoxic effects of these therapeutic agents. However, a clear patient benefit for the latter application has not been demonstrated yet.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-319-91442-8_15

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 59 references

Cited by

See all 119

Metadata

Authors
Bochum, S., Berger, S., & Martens, U. M.
Affiliations
SLK-Kliniken Heilbronn (DE)
Corresponding author
Bochum, Sylvia
Venue
Recent Results in Cancer Research
Published
2018
Volume
211
Pages
217-233
ISSN
  • 0080-0015 (ISSN-L)
  • 2197-6767
OpenAlex
W4255412302
Cited by
104
References
59
Citations by year
2026: 14 · 2025: 14 · 2024: 17 · 2023: 22 · 2022: 16 · 2021: 12 · 2020: 6 · 2019: 3
FWCI
13.93
Type
book chapter
Language
en
Open access
closed
Locations
  • Recent results in cancer research/Recent Results in Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
olaparib, PARP inhibitors, PARP1, PARP2, base excision repair, single-strand breaks, DNA double-strand break repair, homologous recombination deficiency, synthetic lethality, BRCA mutations, recurrent ovarian cancer, metastatic breast cancer, metastatic prostate cancer, radiosensitization, chemosensitization
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Humans, Neoplasms, Phthalazines, Piperazines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Olaparib. https://app.cochat.ai/papers/10.1007/978-3-319-91442-8_15
The paper
Bochum, S., Berger, S., & Martens, U. M. (2018). Olaparib. Recent Results in Cancer Research. https://doi.org/10.1007/978-3-319-91442-8_15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.